



LSHGD: A database for human leprosy susceptible genes

C. George Priya Doss ^{a,*}, N. Nagasundaram ^b, Jain Srajan ^b, Chakraborty Chiranjib ^b

^a Medical Biotechnology Division, School of Biosciences and Technology, Center for Nanobiotechnology, VIT University, Vellore 632014, Tamil Nadu, India

^b School of Biosciences and Technology, VIT University, Vellore 632014, Tamil Nadu, India

ARTICLE INFO

Article history:

Received 21 March 2012

Accepted 23 June 2012

Available online 30 June 2012

Keywords:

Leprosy
Human
SNPs
Database

ABSTRACT

Studies aiming to explore the involvement of host genetic factors to determine susceptibility to develop disease and individual's response to the infection with *Mycobacterium leprae* have increased in recent years. To address this issue, we have developed a Leprosy Susceptible Human Gene Database (LSHGD) to integrate leprosy and human associated 45 genes by profound literature search. This will serve as a user-friendly and interactive platform to understand the involvement of human polymorphisms (SNPs) in leprosy, independent genetic control over both susceptibility to leprosy and its association with multi-drug resistance of *M. leprae*. As the first human genetic database in leprosy it aims to provide information about the associated genes, corresponding protein sequences, available three dimensional structures and polymorphism related to leprosy. In conclusion, this will serve as a multifunctional valuable tool and convenient information platform which is freely available at <http://www.vit.ac.in/leprosy/leprosy.htm> and enables the user to retrieve information of their interest.

© 2012 Elsevier Inc. All rights reserved.

1. Introduction

The field of human genetics of infectious diseases aims to define the genetic variations accounting for inter-individual variability in the course of human infections [1]. Leprosy (Hansen's disease) is a chronic granulomatous infectious disease of human whose etiological agent, *Mycobacterium leprae*, was identified by G. H. A. Hansen in the 19th century. In 2011, there were new cases reported, predominantly in Asia, Africa, and Latin America [2]. According to official reports received from WHO during 2011 from 130 countries and territories, the global registered prevalence of leprosy at the beginning of 2011 stood at 192,246 cases, while the number of new cases detected during 2010 was 228,474 (excluding the small number of cases in Europe). Leprosy is an unusual disease in many aspects, not the least of which is that, despite effective multi-drug therapy, the steady state number of leprosy cases is about equal to the annual number of new cases. These numbers are evidence of a high transmission rate. Until the modes and sources of transmission are well understood, it is unlikely that we will be able to interfere with the transmission or be able to eradicate this disease. Leprosy is primarily a disease of the skin and peripheral nervous system. There were also studies that involved the eyes, bone, lymph nodes, nasal structures, and testes [3]. The Ridley–Jopling classification uses histopathological and clinical features and the bacteriological index as well. It classifies leprosy in tuberculoid (TT), borderline tuberculoid (BT), borderline (BB), borderline-lepromatous (BL), and lepromatous

(LL) categories. In another classification by WHO, multibacillary leprosy includes the lepromatous (LL), borderline lepromatous (BL), and borderline (BB) forms, and paucibacillary leprosy encompasses the tuberculoid (TT) and borderline tuberculoid (BT) forms [4]. During the past years, few studies aiming to explore the host susceptibility to leprosy have been explored and published. The results of epidemiological studies (twin studies and complex segregation analyses) [5–7] and genome-wide analysis (linkage and association) [8] in leprosy infection clearly indicated the involvement of host genetic factors to determine susceptibility to develop the disease and the individual's response to the infection with *M. leprae*. Host genetic factors may therefore largely determine which exposed individuals develop disease. Several studies indicate that leprosy pathogenesis is a three-step process (i) group of genes controls susceptibility to infection, (ii) different genes control the clinical manifestation of disease, and (iii) genes influencing the development, in a proportion of affected individuals, of leprosy reversal reaction type 1 (RR1). A recent human genome-wide linkage or association studies have observed a significant association with or linked to leprosy in various genes *C3*, *C4B*, *CCDC122*, *CCL3*, *CCL5*, *CFB*, *COL3A1*, *CR1*, *CTLA4*, *DEFB1*, *FCN2*, *HLA-DQA1*, *HLA-DQB1*, *HLA-DRB1*, *HSPA1A*, *ICAM1*, *IFNG*, *IL10*, *IL12B*, *IL12RB1*, *IL12RB2*, *LACC1*, *LAMA2*, *LRRK2*, *LTA*, *LTA4H*, *MBL2*, *MICA*, *MICB*, *MRC1*, *NOD2*, *PACRG*, *PARK2*, *PGL1/SDHD*, *RIPK2*, *SLC11A1*, *TAP1*, *TIRAP*, *TLR1*, *TLR2*, *TLR4*, *TNF*, and *TNFSF15*, [5,9–11]. Recent advances in high-throughput genotyping, next generation sequencing, and very high-density microarrays have generated a tremendous amount of human genetic variation data associated with human traits and diseases especially Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), and Insertions and deletions (Indels). There were quite a lot of studies that have reported the direct

* Corresponding author at: VIT University, Vellore 632014, Tamil Nadu, India.
E-mail addresses: georgecp77@yahoo.co.in, georgepriyadoss@vit.ac.in
(C. George Priya Doss).

involvement of SNPs in host genetics susceptibility to leprosy. SNPs provide an opportunity to understand the association between genotype and phenotype in a much broader manner. These mounting studies on SNPs insist their role in better understanding the resultant phenotypic variations among individuals with an endeavor towards new drug design and development. Mapping of SNPs to protein domains and analyzing at the structural level will reveal the full extent to which they can alter the interactivity of proteins. To understand the key structural changes induced by SNPs, we have included three dimensional (3D) structures of the corresponding proteins in this database. Although human associated studies related to leprosy have received great attention from experimental researchers; there is no single comprehensive database to address human leprosy associated gene information. The amount of genetic data generating will also increase drastically in the coming years. To address this issue the need for a comprehensive and well organized collection of genetic data from multiple published studies is urgently needed to provide information in one cluster. Currently there are few databases available related to leprosy such as The Leprosy VNTR Database [12], the Leprosy–Mycobacterium Leprae Database [13], and the Database of Drug Targets for Resistant Pathogens (DDTRP) [14] stating the information related to *M. leprae* and its drug resistance. In this present study, we describe a new web based interface called LSHGD which provides detailed information for researchers who are interested in analyzing the involvement and association of human genome in leprosy. Our main urge is to provide a convenient information platform for molecular epidemiologists and clinicians working on leprosy. The information about the 45 leprosy susceptible human genes [15–56] is shown in Table 1. A primary function of the database is to provide a way of identifying associated SNPs that are likely to have an impact on molecular function. As the first database, freely accessible LSHGD aims to provide comprehensive sets of genetic information both at the sequence and structural levels for extending functional analysis.

2. Data collection

The main goal of our presented work is to develop an interface that provides a direct link between leprosy and human associated genes. The gene information regarding human leprosy susceptible genes [15–56] are provided in Table 1. The data contents can scale up in two ways. (i) The literature information on the impact of human genes and its association with leprosy were compiled from published literatures according to Pub Med (<http://www.ncbi.nlm.nih.gov/PubMed/>), OMIM (<http://www.ncbi.nlm.nih.gov/omim/>), and UniProtKB (<http://www.uniprot.org/>) [57]. OMIM contains textual information, pictures, and reference information. It also contains copious links to NCBI's Entrez database of MEDLINE articles and sequence information. UniProt was used to validate the involvement of gene in mutation; where this gene is implicated: diseases, a selected bibliography with hyperlinks to MEDLINE abstracts. (ii) The genomic information types include genes, chromosomal regions, natural variants (SNPs), associated proteins and their pathways, etc. The SNP information of associated genes was retrieved from the NCBI dbSNP (<http://www.ncbi.nlm.nih.gov/snp/>). The annotated sequence is required to determine the functional class (nsSNP, cds-synon, UTR, and intronic) of the SNP. Nucleotide coordinates (numerical position of a nucleotide in a gene sequence) and genotypic variation information were also obtained from this sequence. We retrieved related information from Public databases and gene annotation includes NCBI [58], OMIM [57], UniProt [59], Ensembl [60], PDB [61], HGNC [62] and KEGG [63].

2.1. Database design

We provide an intuitive, well organized and user friendly web interface that allows users to explore the detailed information of leprosy susceptible human genes. It includes gene name, gene ID, chromosome

Table 1
List of leprosy susceptible human genes.

Gene symbol	Chromosomal position	Description	Reference
<i>C2</i>	6p21.33	Complement component 2	[15]
<i>C3</i>	19p13.3	Complement component 3	[16]
<i>C4B</i>	6p21.33	C4b-binding protein	[17]
<i>CCDC122</i>	13q14.11	Coiled-coil domain containing 122	[18]
<i>CCL3</i>	17q12	Chemokine (C–C motif) ligand 3	[19]
<i>CCL5</i>	17q11	Chemokine (C–C motif) ligand 5	[20]
<i>CFB</i>	6p21.33	Complement factor B	[21]
<i>COL3A1</i>	2q32.2	Collagen, type III, alpha 1	[22]
<i>CR1</i>	1q32.2	Complement receptor 1	[23]
<i>CTLA4</i>	2q33.2	Cytotoxic t-lymphocyte antigen 4	[24]
<i>DEFB1</i>	8p23.1	Defensin, beta 1	[25]
<i>FCN2</i>	9q34.3	Ficolin-2	[26]
<i>HLA-DQA1</i>	6p21.3	HLA class II histocompatibility antigen, DQ alpha 1	[27]
<i>HLA-DQB1</i>	6p21.3	HLA class II histocompatibility antigen, DQ beta 1	[28]
<i>HLA-DRB1</i>	6p21.32	HLA class II histocompatibility antigen, DR beta 1	[29]
<i>HSPA1A</i>	6p21.33	Heat shock 70 kDa protein 1A	[30]
<i>ICAM1</i>	19p13.2	Intercellular adhesion molecule 1	[31]
<i>IFNG</i>	12q14	Interferon-gamma (IFN- γ)	[32]
<i>IL10</i>	1q31–q32	Interleukin-10	[33]
<i>IL12B</i>	5q33.3	Human interleukin 12	[34]
<i>IL12RB1</i>	19p13.11	Interleukin 12 receptor, beta 1	[35]
<i>IL12RB2</i>	1p31.3	Interleukin 12 receptor, beta 2	[36]
<i>LACC1</i>	13q14.11	Laccase (multicopper oxidoreductase) domain containing 1	[18]
<i>LAMA2</i>	6q22–q23	Laminin subunit alpha-2	[37]
<i>LRRK2</i>	12q12	Leucine-rich repeat kinase 2	[38]
<i>LTA</i>	6p21.3	Lymphotoxin-alpha	[39]
<i>LTA4H</i>	12q22	Leukotriene A4 hydrolase	[40]
<i>MBL2</i>	10q11.2	Mannose-binding lectin	[41]
<i>MICA</i>	6p21.33	MHC class I polypeptide-related sequence	[42]
<i>MICB</i>	6p21.33	MHC class I polypeptide-related sequence B	[43]
<i>MRC1</i>	10p12.33	Mannose receptor, C type 1	[44]
<i>NOD2</i>	16q21	Nucleotide-binding oligomerization domain-containing protein 2	[45]
<i>PACRG</i>	6q26	Parkin coregulated gene	[46]
<i>PARK2</i>	6q25.2–q27	Parkin protein 2, E3 ubiquitin protein ligase	[47]
<i>PGL1/SDHD</i>	11q23	Succinate dehydrogenase complex subunit D	[48]
<i>RIPK2</i>	8q21	Receptor-interacting serine/threonine–protein kinase 2	[49]
<i>SLC11A1</i>	2q35	Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1	[50]
<i>TAP1</i>	6p21.3	Antigen peptide transporter 1	[51]
<i>TIRAP</i>	11q24.2	Toll-interleukin 1 receptor	[52]
<i>TLR1</i>	4p14	Toll-like receptor 1	[53]
<i>TLR2</i>	4q32	Toll-like receptor 2	[53]
<i>TLR4</i>	9q33.1	Toll-like receptor 4	[53]
<i>TNF</i>	6p21.33	Tumor necrosis factor-alpha	[54]
<i>TNFSF15</i>	9q32	Tumor necrosis factor (ligand) superfamily, member 15	[55]
<i>VDR</i>	12q13	Vitamin D (1,25-dihydroxyvitamin D3) receptor	[56]

number, chromosomal position, chromosomal orientation, gene function, taxonomic identifier, RefSeq_protein, RefSeq_mRNA, OMIM ID, HGNC ID, Pub Med ID, genotypic variation, residue change, function class, SNP reference, associated protein, associated PDB ID, UniProt ID, and associated pathways. Majorly, sequence information was incorporated from NCBI (DNA), protein related information from UniProt and protein structures from PDB. Clicking links leads to more detailed information.

2.2. LSHGD organization and system design

Upon accessing LSHGD (Link: <http://www.vit.ac.in/leprosy/leprosy.htm>) a click on the first interactive button named “Home” introduces the user about the database. A click on the second interactive button

named “Gene Database” allows the user to specifically choose the type of information from the check box menu that includes gene information, chromosomal information, associated protein information, and natural variants information from the database. A click on the third interactive button named “Classification of Gene”, allows the user to visualize the classification of human genes susceptible to leprosy based on associated protein mechanisms. A click on the last interactive button named “Associated protein study” allows the user to find several other protein associated studies in different stages of leprosy. A click on the last interactive button named “Link to Other Database” allows user to link other related databases Leprosy–Mycobacterium Leprae Database [13], and Database of Drug Targets for Resistant Pathogens (DDTRP). The following interfaces are displayed in Fig. 1. LSHGD consists of three major software components: an Apache HTTP server, a MySQL database and an Aspx script. The back end data analysis programs were written in asp script using the Microsoft Visual Studio 2008 tool.

2.3. Database implementation

A maximum of 45 genes are displayed in the interface. In gene information the interface provides related information such as Gene Symbol, Gene Name, Gene Function, Entrez Gene ID, RefSeq_Protein, RefSeq_mRNA, OMIM_ID, PubMed_ID, HGNC_ID, Primary Reference related to leprosy susceptibility, population studied, pathway Information and other cross references. Pathway information for each gene allows the user to identify disease related and associated pathways. Ethnicity will provide information about the predisposition of leprosy genes in different populations. Similarly, Gene_Name, Gene_ID, Chromosome_Number, Chromosomal_Position and Orientation in Chromosomal Information have been provided. These information will definitely provide the user the information about susceptibility of genes in a specific chromosomal region. Notably, gene information and chromosome information will serve as genomic platform for database users. To explore the possible relationships between genes and diseases we have incorporated information about natural variants. However, only a small subset of SNP information has been documented. It is

easy to determine a preliminary profile of the relationship between genes and diseases using the information such as Gene Symbol, Entrez Gene ID, Associated SNP, Genotypic Variation, Residue Change, Functional Annotation, Consequence of Transcript and SNP Associated with other Disease. Information such as functional annotation and consequence of transcript encoded have been provided for the significant SBNPs by GWAS and pathway information for each gene in the natural variants and gene information interface of the revised database. Similarly, Gene Name, Associated protein, Chromosomal position, UniProt_ID, Associated_PDB_ID and Associated_Pathway in protein information exist. From this natural variants and protein information result table, the user can interlink SNP associated information at the structural level. These interfaces created in this database will satisfy the demands of the scientific community by providing in depth knowledge about leprosy association with human variants.

2.4. Designed instruction for users

The freely accessible LSHGD available at <http://www.vit.ac.in/leprosy/leprosy.htm> aims to provide a comprehensive set of genetic information both at the sequence and structural levels for extending functional analysis. The database is composed of five interactive buttons in the main display (Fig. 2) and explained their functions by considering TLR1 as example.

- (i) Main Page: the database is composed of five interactive buttons in the main display namely Home, Gene Database, Classification of genes, Associated protein study and Link to other databases. Home is the main page of the database. By clicking, the user can access the summarized introduction about the database (Fig. 2A).
- (ii) Gene Database: This represents the main characteristics of 45 leprosy susceptible human genes. Search for genes in LSHGD by using the drop down menu provided in the interface. From this page the user has the option of retrieving information of their choice such as Gene Information (Fig. 2B), Chromosomal Information (Fig. 2C), Natural Variants Information




Fig. 1. Overview of the structural and functional workflows of LSHGD.




Fig. 2. Snapshot of LSHGD to access and analyze the data associated with leprosy genes. A) Home page of the LSHGD, B) Gene Information, C) Chromosomal Information, D) Natural Variants Information, E) Protein Information, and F) Associated protein study.

(Fig. 2D), and Protein Information (Fig. 2E) by using four radio buttons. These information will provide in depth knowledge about the gene function, population studied, SNP information, annotation, consequence of transcript, primary reference associated with the disease and other cross references.

- (iii) Classification of genes: This page displays the classification of 45 genes namely Innate Immune Receptors Genes (6), Cytokines Genes (3), Transport Genes (1), Tissue-Specific Markers Genes (1), Innate Immune Effectors Molecules and Serum Proteins Genes (3), and Other Candidate Genes (31).
- (iv) Associated protein studies: This page (Fig. 2F) represents other associated proteins in different stages of leprosy namely LL, BL, BB, TT, BT, Reversal reactions (RRs) and Erythema nodosum leprosum (ENL).
- (v) Link to other databases: This page displays two interlinked database links which will be helpful in understanding multi-drug resistance in leprosy.

3. Future improvement

As the amount of genomic information generating will be increasing drastically in the coming years, we will continuously collect the latest gene and SNP related data disease data sets to keep up-to-date. In the future we would like to improve our database in three main ways. One is to further provide link gene symbol to their corresponding accession numbers in NCBI (NP for protein and NM for mRNA). Next is to provide link to PDB ID information. Lastly, the incorporation of *in silico* tool prediction results into database will be able to classify SNPs pathogenic from neutral ones. We assure this information will definitely will make

a way for genotype–phenotype researches as well as pharmacogenetics studies.

Conflict of interest

The authors declare that we don't have a conflict of interest.

Acknowledgment

The authors thank the management of VIT University for providing the facilities to carry out this work.

References

- [1] J.L. Casanova, L. Abel, Human genetics of infectious diseases: a unified theory, *EMBO J.* 26 (2007) 915–922.
- [2] F.O. Vannberg, S.J. Chapman, A.V. Hill, Human genetic susceptibility to intracellular pathogens, *Immunol. Rev.* 240 (2011) 105–116.
- [3] S.L. Walker, D.N. Lockwood, Leprosy, *Clin. Dermatol.* 25 (2007) 165–172.
- [4] R.R. Jacobson, J.L. Krahenbuhl, Leprosy, *Lancet* 353 (1999) 655–660.
- [5] A. Alter, A. Grant, L. Abel, A. Alcais, E. Schurr, Leprosy as a genetic disease, *Int. Mamm. Genome Soc.* 22 (2011) 19–31.
- [6] M.R. Chakravarti, F. Vogel, A twin study on leprosy, *Top Hum. Genet.* 1 (1973) 1–123.
- [7] L. Abel, D.L. Vu, J. Oberti, V.T. Nguyen, V.C. Van, M. Guilloud-Bataille, E. Schurr, P.H. Lagrange, Complex segregation analysis of leprosy in southern Vietnam, *Genet. Epidemiol.* 12 (1995) 63–82.
- [8] C.C. Cardoso, A.C. Pereira, C. de Sales Marques, M.O. Moraes, Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome, *Future Microbiol.* 6 (2011) 533–549.
- [9] E.A. Misch, W.R. Berrington, J.C. Vary Jr., T.R. Hawn, Leprosy and the human genome, *Microbiol. Mol. Biol. Rev.* 74 (2010) 589–620.
- [10] E. Prado Montes de Oca, Human polymorphisms as clinical predictors in leprosy, *J Trop Med.* 2011 (2011) 923943.

- [11] F.R. Zhang, et al., Genomewide association study of leprosy, *N. Engl. J. Med.* 361 (2009) 2609–2618.
- [12] B.G. Hall, A *Mycobacterium leprae* VNTR database, *Lepr. Rev.* 81 (2010) 96–98.
- [13] A. Kapopoulou, J.M. Lew, S.T. Cole, The MycoBrowser portal: a comprehensive and manually annotated resource for mycobacterial genomes (Edinb), *Tuberculosis* 91 (2011) 8–13.
- [14] J.C. Sundaramurthi, P. Ramanandan, S. Brindha, C.R. Subhasree, A. Prasad, V. Kumaraswami, L.E. Hanna, DDTRP: database of drug targets for resistant pathogens, *Bioinformatics* 7 (2011) 98–101.
- [15] M.H. de Bruijn, G.H. Fey, Human complement component C3: cDNA coding sequence and derived primary structure, *Proc. Natl. Acad. Sci.* 82 (1985) 708–712.
- [16] M.H. Roos, E. Mollenhauer, P. Demant, C. Rittner, A molecular basis for the two locus model of human complement component C4, *Nature* 298 (1982) 854–856.
- [17] B.O. Smith, R.L. Mallin, M. Krych-Goldberg, X. Wang, R.E. Hauhart, K. Bromek, D. Uhrin, J.P. Atkinson, P.N. Barlow, Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor, *Cell* 108 (2002) 769–780.
- [18] S.H. Wong, A.V.S. Hill, F.O. Vannberg, Genomewide association study of leprosy, *N. Engl. J. Med.* 362 (2010) 1446–1447.
- [19] M. Nakao, H. Nomiya, K. Shimada, Structures of human genes coding for cytokine LD78 and their expression, *Mol. Cell. Biol.* 10 (1990) 3646–3658.
- [20] T.A. Donlon, A.M. Krensky, M.R. Wallace, F.S. Collins, M. Lovett, C. Clayberger, Localization of a human T-cell-specific gene, RANTES (D17S136E), to chromosome 17q11.2–q12, *Genomics* 5 (1990) 548–553.
- [21] R.D. Campbell, The molecular genetics and polymorphism of C2 and factor B, *Br. Med. Bull.* 43 (1987) 37–49.
- [22] R.A. Janeczko, F.F. Ramirez, Nucleotide and amino acid sequences of the entire human alpha-1(III) collagen, *Nucleic Acids Res.* 17 (1989) 6742.
- [23] K.W. Bensch, M. Raida, H.J. Magert, P. Schulz-Knappe, W.G. Forssmann, hBD-1: a novel beta-defensin from human plasma, *FEBS Lett.* 368 (1995) 331–335.
- [24] P. Dariavach, M.-G. Mattei, P. Golstein, M.-P. Lefranc, Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains, *Eur. J. Immunol.* 18 (1988) 1901–1905.
- [25] K. Yamamoto, H. Kobayashi, O. Miura, S. Hirosawa, N. Miyasaka, Assignment of IL12RB1 and IL12RB2, interleukin-12 receptor beta-1 and beta-2 chains, to human chromosome 19 band p13.1 and chromosome 1 band p31.2, respectively, by *in situ* hybridization, *Cytogenet. Cell Genet.* 77 (1997) 257–258.
- [26] Y. Endo, Y. Sato, M. Matsushita, T. Fujita, Cloning and characterization of the human lectin P35 gene and its related gene, *Genomics* 36 (1996) 515–521.
- [27] R.J. Duquesnoy, M. Marrari, K. Annen, Identification of an HLA-DR associated system of B cell alloantigens, *Transplant. Proc.* 11 (1979) 1757–1760.
- [28] J.A. Todd, J.I. Bell, H.O. McDewitt, HLA-DQ(beta) gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus, *Nature* 329 (1987) 599–604.
- [29] T.F. Bergstrom, A. Josefsson, H.A. Erlich, U. Gyllensten, Recent origin of HLA-DRB1 alleles and implications for human evolution, *Nat. Genet.* 18 (1998) 237–242.
- [30] C.M. Milner, R.D. Campbell, Structure and expression of the three MHC-linked HSP70 genes, *Immunogenetics* 32 (1990) 242–251.
- [31] J.M. Greve, G. Davis, A.M. Meyer, C.P. Forte, S.C. Yost, C.W. Marlor, M.E. Kamarck, A. McClelland, The major human rhinovirus receptor is ICAM-1, *Cell* 56 (1989) 839–847.
- [32] S.L. Naylor, A.Y. Sakaguchi, T.B. Shows, M.L. Law, D.V. Goeddel, P.W. Gray, Human immune interferon gene is located on chromosome 12, *J. Exp. Med.* 157 (1983) 1020–1027.
- [33] J. Eskdale, D. Kube, H. Tesch, G. Gallagher, Mapping of the human IL10 gene and further characterization of the 5-prime flanking sequence, *Immunogenetics* 46 (1997) 120–128.
- [34] D. Huang, M.R. Cancilla, G. Morahan, Complete primary structure, chromosomal localisation, and definition of polymorphisms of the gene encoding the human interleukin-12 p40 subunit, *Genes Immun.* 1 (2000) 515–520.
- [35] C. Fieschi, et al., Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta-1 deficiency: medical and immunological implications, *J. Exp. Med.* 197 (2003) 527–535.
- [36] K. Yamamoto, H. Kobayashi, O. Miura, S. Hirosawa, N. Miyasaka, Assignment of IL12RB1 and IL12RB2, interleukin-12 receptor beta-1 and beta-2 chains, to human chromosome 19 band p13.1 and chromosome 1 band p31.2, respectively, by *in situ* hybridization, *Cytogenet. Cell Genet.* 77 (1997) 257–258.
- [37] R. Vuolteenaho, M. Nissinen, K. Sainio, M. Byers, R. Eddy, H. Hirvonen, T.B. Shows, H. Sariola, E. Engvall, K. Tryggvason, K. Human, laminin M chain (merosin): complete primary structure, chromosomal assignment, and expression of the M and A chain in human fetal tissues, *J. Cell Biol.* 124 (1994) 381–394.
- [38] A. Zimprich, Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, *Neuron* 44 (2004) 601–607.
- [39] B.B. Aggarwal, T.E. Eessalu, P.E. Hass, Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon, *Nature* 318 (1985) 665–667.
- [40] J.A. Mancini, J.F. Evans, Cloning and characterization of the human leukotriene A-4 hydrolase gene, *Eur. J. Biochem.* 231 (1995) 65–71.
- [41] K. Sastry, G.A. Herman, L. Day, E. Deignan, G. Bruns, C.C. Morton, R.A.B. Ezekowitz, The human mannose-binding protein gene: exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10, *J. Exp. Med.* 170 (1989) 1175–1189.
- [42] S. Bahram, M. Bresnahan, D.E. Geraghty, T. Spies, A second lineage of mammalian major histocompatibility complex class I genes, *Proc. Natl. Acad. Sci.* 91 (1994) 6259–6263.
- [43] S.R. Nalabolu, H. Shukla, G. Nallur, S. Parimoo, S.M. Weissman, Genes in a 220-kb region spanning the TNF cluster in human MHC, *Genomics* 31 (1996) 215–222.
- [44] S.J. Kim, N. Ruiz, K. Bezouska, K. Drickamer, Organization of the gene encoding the human macrophage mannose receptor (MRC1), *Genomics* 14 (1992) 721–727.
- [45] Y. Ogura, N. Inohara, A. Benito, F.F. Chen, S. Yamaoka, G. Nunez, Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappa-B, *J. Biol. Chem.* 276 (2001) 4812–4818.
- [46] A.B. West, P.J. Lockhart, C. O'Farrell, M.J. Farrer, Identification of a novel gene linked to parkin via a bi-directional promoter, *J. Mol. Biol.* 326 (2003) 11–19.
- [47] T. Kitada, S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, S. Minoshima, M. Yokochi, Y. Mizuno, N. Shimizu, Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, *Nature* 392 (1998) 605–608.
- [48] H. Hirawake, M. Taniwaki, A. Tamura, S. Kojima, K. Kita, Cytochrome b in human complex II (succinate-ubiquinone oxidoreductase): cDNA cloning of the components in liver mitochondria and chromosome assignment of the genes for the large (SDHC) and small (SDHD) subunits to 1q21 and 11q23, *Cytogenet. Cell Genet.* 79 (1997) 132–138.
- [49] N. Inohara, L. del Peso, T. Koseki, S. Chen, G. Nunez, RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis, *J. Biol. Chem.* 273 (1998) 12296–12300.
- [50] F. Kishi, Isolation and characterization of human NRAMP cDNA, *Biochem. Biophys. Res. Commun.* 204 (1994) 1074–1080.
- [51] T. Spies, M. Bresnahan, S. Bahram, D. Arnold, G. Blanck, E. Mellins, D. Pious, R. DeMars, A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway, *Nature* 348 (1990) 744–747.
- [52] T. Horng, G.M. Barton, R. Medzhitov, TIRAP: an adapter molecule in the Toll signaling pathway, *Nat. Immun.* 2 (2001) 835–841.
- [53] F.L. Rock, G. Hardiman, J.C. Timans, R.A. Kastelein, J.F. Bazan, A family of human receptors structurally related to *Drosophila* Toll, *Proc. Natl. Acad. Sci.* 95 (1998) 588–593.
- [54] L.J. Old, Tumor necrosis factor (TNF), *Science* 230 (1985) 630–632.
- [55] Y. Zhai, J. Ni, G.W. Jiang, J. Lu, L. Xing, C. Lincoln, K.C. Carter, F. Janat, D. Kozak, S. Xu, L. Rojas, B.B. Aggarwal, S. Ruben, L.Y. Li, R. Gentz, G.L. Yu, VEG1, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas *in vivo*, *FASEB J.* 13 (1999) 181–189.
- [56] A.R. Baker, D.P. McDonnell, M. Hughes, T.M. Crisp, D.J. Mangelsdorf, M.R. Haussler, J.W. Pike, J. Shine, B.W. O'Malley, Cloning and expression of full-length cDNA encoding human vitamin D receptor, *Proc. Natl. Acad. Sci.* 85 (1988) 3294–3298.
- [57] J. Amberger, C.A. Bocchini, A.F. Scott, A. Hamosh, McKusick's Online Mendelian Inheritance in Man (OMIM), *Nucleic Acids Res.* 37 (2009) D793–D796.
- [58] S.T. Sherry, et al., dbSNP: the NCBI database of genetic variation, *Nucleic Acids Res.* 29 (2001) 308–311.
- [59] A. Bairoch, R. Apweiler, The SWISS-PROT protein sequence data bank and its new supplement TREMBL, *Nucleic Acids Res.* 24 (1996) 21–25.
- [60] P. Flicek, et al., Ensembl 2011, *Nucleic Acids Res.* 39 (2011) D800–D806.
- [61] A. Kouranov, et al., The RCSB PDB information portal for structural genomics, *Nucleic Acids Res.* 34 (2006) D302–5.
- [62] R.L. Seal, S.M. Gordon, M.J. Lush, M.W. Wright, E.A. Bruford, genenames.org: the HGNC resources in 2011, *Nucleic Acids Res.* 39 (2011) D514–D519.
- [63] M. Kanehisa, S. Goto, M. Hattori, K.F. Aoki-Kinoshita, M. Itoh, S. Kawashima, T. Katayama, M. Araki, M. Hirakawa, From genomics to chemical genomics: new developments in KEGG, *Nucleic Acids Res.* 34 (2006) D354–D357.